ERNA Stock Overview
A life science company, provides mRNA cell engineering technologies. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Eterna Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.52 |
| 52 Week High | US$2.63 |
| 52 Week Low | US$0.52 |
| Beta | 7.77 |
| 11 Month Change | -48.57% |
| 3 Month Change | -71.11% |
| 1 Year Change | -46.97% |
| 33 Year Change | -99.58% |
| 5 Year Change | n/a |
| Change since IPO | -99.45% |
Recent News & Updates
Shareholder Returns
| ERNA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -37.7% | 2.5% | 2.2% |
| 1Y | -47.0% | 16.1% | 31.6% |
Return vs Industry: ERNA underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: ERNA underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| ERNA volatility | |
|---|---|
| ERNA Average Weekly Movement | 14.3% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ERNA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ERNA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 8 | Sanjeev Luther | eternatx.com |
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.
Eterna Therapeutics Inc. Fundamentals Summary
| ERNA fundamental statistics | |
|---|---|
| Market cap | US$26.71m |
| Earnings (TTM) | -US$44.95m |
| Revenue (TTM) | US$598.00k |
44.7x
P/S Ratio-0.6x
P/E RatioIs ERNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ERNA income statement (TTM) | |
|---|---|
| Revenue | US$598.00k |
| Cost of Revenue | US$162.00k |
| Gross Profit | US$436.00k |
| Other Expenses | US$45.39m |
| Earnings | -US$44.95m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.87 |
| Gross Margin | 72.91% |
| Net Profit Margin | -7,516.56% |
| Debt/Equity Ratio | -81.4% |
How did ERNA perform over the long term?
See historical performance and comparison